Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Channel of Togo.
Press releases published on June 27, 2025
Results of Annual General Meeting
GlobeNewswire
·
June 27, 2025
June 27, 2023 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment …
Laboratory Information Management System Market worth US$5.19 billion by 2030 with 12.5% CAGR | MarketsandMarkets™.
GlobeNewswire
·
June 27, 2025
Delray Beach, FL, June 27, 2025 (GLOBE NEWSWIRE) -- The global laboratory information management system market, valued at US$2.54 billion in 2024, stood at US$2.88 billion in 2025 and is projected to advance at a resilient CAGR of 12.5% from 2025 to 2030, …
Helius Medical Technologies Announces Reverse Stock Split
GlobeNewswire
·
June 27, 2025
NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced …
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
GlobeNewswire
·
June 27, 2025
TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway …
CorMedix Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewswire
·
June 27, 2025
BERKELEY HEIGHTS, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced the pricing of …
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
GlobeNewswire
·
June 27, 2025
Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc …
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
·
June 27, 2025
WATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic …
Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology
GlobeNewswire
·
June 27, 2025
Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP …
Calidi Biotherapeutics Announces Shareholder Letter from CEO
GlobeNewswire
·
June 27, 2025
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic …
Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
GlobeNewswire
·
June 27, 2025
GLO targets the growing ”beauty-from-within” market with scientifically proven cellular defense and skin vitality benefits Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a …
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
GlobeNewswire
·
June 27, 2025
Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated Presentation at the Phoenix Best Science Series by …
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
GlobeNewswire
·
June 27, 2025
EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) today announced that they have entered into a …
FOXO TECHNOLOGIES INC. DESIGNATES NEW SERIES OF PREFERRED STOCK TO BE USED FOR ACQUISITIONS
GlobeNewswire
·
June 27, 2025
WEST PALM BEACH, FLORIDA, June 27, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that it has designated a new series of its preferred stock (Series E Cumulative Redeemable Secured Preferred …
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
GlobeNewswire
·
June 27, 2025
—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate …
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
GlobeNewswire
·
June 27, 2025
BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in …
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
GlobeNewswire
·
June 27, 2025
DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will …
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
GlobeNewswire
·
June 27, 2025
ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases …
Orphalan Partners with MAP International and the Wilson Disease Association to Provide Life-Changing Medicine to Underserved Communities
GlobeNewswire
·
June 27, 2025
FOR IMMEDIATE RELEASE Orphalan Partners with MAP International and the Wilson Disease Association to Provide Life-Changing Medicine to Underserved Communities Paris, France —27, June, 2025— Orphalan SA, a global pharmaceutical company focused on rare …
Tilray Medical veröffentlicht bahnbrechende Forschungsergebnisse zur Pharmakokinetik von THC- und CBD-Formulierungen
GlobeNewswire
·
June 27, 2025
NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, ein Geschäftsbereich von Tilray Brands, Inc. („Tilray” oder das „Unternehmen”) (Nasdaq: TLRY; TSX: TLRY) und ein weltweit führender Anbieter von medizinischem Cannabis, der die therapeutische …
Tilray Medical publie une recherche pionnière sur la pharmacocinétique des formulations de THC et de CBD
GlobeNewswire
·
June 27, 2025
NEW YORK, 27 juin 2025 (GLOBE NEWSWIRE) -- Tilray Medical, une division de Tilray Brands, Inc. (« Tilray » ou la « Société ») (Nasdaq : TLRY ; TSX : TLRY) et leader mondial du cannabis thérapeutique, qui favorise l’alliance thérapeutique entre les patients …